WEBULL
News
XRTX
0.5961
-2.26%
-0.0138
Weekly Report: what happened at XRTX last week (1229-0102)?
Weekly Report · 1d ago
XORTX Highlights New Gout Genetics Research, Reshapes Board and Clarifies Financing as Vectus Deal Nears Closing
TipRanks · 3d ago
XORTX Awaits ASX Approval to Close Acquisition of Renal Anti-Fibrotic Program from Vectus
Reuters · 3d ago
XORTX Leans Into Genetic Breakthroughs in Gout as It Reshapes Board and Advances Oxypurinol
TipRanks · 12/31/2025 23:37
XORTX Awaits ASX Decision on Closing Vectus Renal Program Acquisition
Reuters · 12/31/2025 23:15
XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update
Barchart · 12/31/2025 17:15
Weekly Report: what happened at XRTX last week (1222-1226)?
Weekly Report · 12/29/2025 10:25
Weekly Report: what happened at XRTX last week (1215-1219)?
Weekly Report · 12/22/2025 10:25
Weekly Report: what happened at XRTX last week (1208-1212)?
Weekly Report · 12/15/2025 10:33
Weekly Report: what happened at XRTX last week (1201-1205)?
Weekly Report · 12/08/2025 10:32
Weekly Report: what happened at XRTX last week (1124-1128)?
Weekly Report · 12/01/2025 10:27
XORTX Therapeutics Inc. unveils investor presentation on XRx-026 for gout and kidney disease pipeline
Reuters · 11/26/2025 19:03
Weekly Report: what happened at XRTX last week (1117-1121)?
Weekly Report · 11/24/2025 10:32
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 11/21/2025 21:05
XORTX Therapeutics Reports Q3 2025 Financial Results
TipRanks · 11/17/2025 21:52
Weekly Report: what happened at XRTX last week (1110-1114)?
Weekly Report · 11/17/2025 10:33
Weekly Report: what happened at XRTX last week (1103-1107)?
Weekly Report · 11/10/2025 10:29
Weekly Report: what happened at XRTX last week (1027-1031)?
Weekly Report · 11/03/2025 10:30
Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket
Benzinga · 11/03/2025 10:09
XORTX Therapeutics Completes $1.1 Million Direct Offering
TipRanks · 10/31/2025 20:56
More
Webull provides a variety of real-time XRTX stock news. You can receive the latest news about Xortx Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About XRTX
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.